UPDATE OF THE DUTCH MANUAL FOR COSTING IN ECONOMIC EVALUATIONS

Objectives: In 2000, the first “Dutch Manual for Costing: Methods and Reference Prices for Economic Evaluations in Healthcare” was published, followed by an updated version in 2004. The purpose of the Manual is to facilitate the implementation and assessment of costing studies in economic evaluations. New developments necessitated the publication of a thoroughly updated version of the Manual in 2010. The present study aims to describe the main changes of the 2010 Manual compared with earlier editions of the Manual. Methods: New and updated topics of the Manual were identified. The recommendations of the Manual were compared with the health economic guidelines of other countries, eliciting strengths and limitations of alternative methods. Results: New topics in the Manual concern medical costs in life-years gained, the database of the Diagnosis Treatment Combination (DBC) casemix System, reference prices for the mental healthcare sector and the costs borne by informal care-givers. Updated topics relate to the friction cost method, discounting future effects and options for transferring cost results from international studies to the Dutch situation. Conclusions: The Action Plan is quite similar to many health economic guidelines in healthcare. However, the recommendations on particular aspects may differ between national guidelines in some respects. Although the Manual may serve as an example to countries intending to develop a manual of this kind, it should always be kept in mind that preferred methods predominantly depend on a country's specific context.

[1]  L. Curtis,et al.  Unit Costs of Health and Social Care 2016 , 2015 .

[2]  A. Morris.  A European Survey , 2013 .

[3]  F. Cots,et al.  Diagnosis related groups in Europe: moving towards transparency, efficiency, and quality in hospitals? , 2013, BMJ.

[4]  S. Tan,et al.  Handleiding voor kostenonderzoek: methoden en referentieprijzen voor economische evaluaties in de gezondheidszorg , 2012, Tijdschrift voor gezondheidswetenschappen.

[5]  W. B. van den Hout,et al.  The value of productivity: human-capital versus friction-cost method , 2009, Annals of the rheumatic diseases.

[6]  Siok Swan Tan.  Microcosting in economic evaluations: Issues of accuracy, feasibility, consistency and generalisability , 2009 .

[7]  F. Rutten,et al.  Comparing methodologies for the cost estimation of hospital services , 2009, The European Journal of Health Economics.

[8]  N. J. Exel,et al.  Unrelated Medical Costs in Life-Years Gained , 2008, PharmacoEconomics.

[9]  J. Wasem,et al.  Empirische Bewertungssätze in der gesundheitsökonomischen Evaluation – ein Vorschlag der AG Methoden der gesundheitsökonomischen Evaluation (AG MEG). , 2005 .

[10]  M. Postma,et al.  Need for differential discounting of costs and health effects in cost effectiveness analyses , 2005, BMJ : British Medical Journal.

[11]  J Raftery,et al.  Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. , 2005, Health technology assessment.

[12]  J Raftery,et al.  Potential use of routine databases in health technology assessment. , 2005, Health technology assessment.

[13]  Risto Lehtonen,et al.  Multilevel Statistical Models , 2005 .

[14]  A. Ludbrook,et al.  Collecting unit cost data in multicentre studies , 2005, The European Journal of Health Economics.

[15]  B. Ferguson,et al.  NHS database of reference costs is severely flawed , 2001, BMJ : British Medical Journal.

[16]  J Hjelmgren,et al.  Health economic guidelines--similarities, differences and some implications. , 2001, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[17]  J. Graf von der Schulenburg,et al.  The influence of economic evaluation studies on decision making. A European survey. The EUROMET group. , 2000, Health policy.

[18]  A. Mcguire,et al.  Centre-specific or average unit costs in multi-centre studies? Some theory and simulation. , 2000, Health economics.

[19]  M J Buxton,et al.  Assessing the costs of healthcare technologies in clinical trials. , 1999, Health technology assessment.

[20]  P. Barnett,et al.  Cost analysis in the Department of Veterans Affairs: consensus and future directions. , 1999, Medical care.

[21]  M. Koopmanschap,et al.  A Practical Guide for Calculating Indirect Costs of Disease , 1996, PharmacoEconomics.

[22]  A. Culyer,et al.  Discounting and decision making in the economic evaluation of health-care technologies. , 2011, Health economics.

[23]  P. van Baal,et al.  Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions? , 2008, PharmacoEconomics.

[24]  J. Wasem,et al.  [Empirical standard costs for health economic evaluation in Germany -- a proposal by the working group methods in health economic evaluation]. , 2005, Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)).

[25]  Richard Willke,et al.  Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[26]  A. Ludbrook,et al.  Collecting unit cost data in multicentre studies. Creating comparable methods. , 2005, The European journal of health economics : HEPAC : health economics in prevention and care.

[27]  Risto Lethonen.  Multilevel Statistical Models (3rd ed.) , 2005 .

[28]  D. Quinton,et al.  Unit Costs of Health and Social Care 2004 , 2004 .

[29]  Milton C Weinstein,et al.  Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[30]  Jan B Oostenbrink,et al.  Standardisation of costs: the Dutch Manual for Costing in economic evaluations. , 2002, PharmacoEconomics.